In BC patients, accurate assessment of hormone receptor (HR), HER2 status, and CK5/6 of the tumor is critical for defining the molecular subtypes and predicting response to systemic therapies [21, 31, 32]. This evidence concerns the gene NR4A1 and breast cancer.